Market closed
Kiniksa Pharmaceuticals/$KNSA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Ticker
$KNSA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
297
Website
KNSA Metrics
BasicAdvanced
$1.4B
-
-$0.13
0.32
-
Price and volume
Market cap
$1.4B
Beta
0.32
52-week high
$27.92
52-week low
$16.56
Average daily volume
523K
Financial strength
Current ratio
3.244
Quick ratio
2.592
Long term debt to equity
1.96
Total debt to equity
2.424
Management effectiveness
Return on assets (TTM)
-3.16%
Return on equity (TTM)
-2.15%
Valuation
Price to revenue (TTM)
3.697
Price to book
3.31
Price to tangible book (TTM)
3.44
Price to free cash flow (TTM)
127.896
Growth
Revenue change (TTM)
54.41%
Earnings per share change (TTM)
22.55%
3-year revenue growth (CAGR)
168.70%
3-year earnings per share growth (CAGR)
-63.21%
What the Analysts think about KNSA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.
KNSA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KNSA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KNSA News
AllArticlesVideos
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
GlobeNewsWire·4 days ago
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
GlobeNewsWire·1 month ago
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kiniksa Pharmaceuticals stock?
Kiniksa Pharmaceuticals (KNSA) has a market cap of $1.4B as of February 24, 2025.
What is the P/E ratio for Kiniksa Pharmaceuticals stock?
The price to earnings (P/E) ratio for Kiniksa Pharmaceuticals (KNSA) stock is 0 as of February 24, 2025.
Does Kiniksa Pharmaceuticals stock pay dividends?
No, Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders as of February 24, 2025.
When is the next Kiniksa Pharmaceuticals dividend payment date?
Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals (KNSA) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.